The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Drugs of UDCA Market Research Report 2024
Synopsis
The drug decreases the absorption of cholesterol and is used to dissolve (cholesterol) gallstones in patients as an alternative to a surgical procedure to remove the gallstones.
The global Drugs of UDCA market was valued at US$ 1645 million in 2023 and is anticipated to reach US$ 3389.8 million by 2030, witnessing a CAGR of 10.7% during the forecast period 2024-2030.
UDCA is a bile acid used in the treatment of various liver disorders, such as primary biliary cholangitis and primary sclerosing cholangitis. The increasing prevalence of these liver diseases, along with growing awareness about their diagnosis and treatment, is driving market growth. Additionally, advancements in drug formulations, such as the development of extended-release and combination therapies, are further contributing to market expansion. The market is highly competitive, with several pharmaceutical companies actively engaged in the production and distribution of UDCA drugs. However, challenges such as high drug costs, side effects, and limited accessibility in certain regions may hinder market growth.
This report aims to provide a comprehensive presentation of the global market for Drugs of UDCA, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drugs of UDCA.
Report Scope
The Drugs of UDCA market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Drugs of UDCA market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Drugs of UDCA manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Dr. Falk Pharma
Daewoong Pharmaceutical
Teva
Epic Pharma
Mitsubishi Tanabe Pharma
Lannett
Mylan
Bruschettini
Impax
Shanghai Pharma
Grindeks
Segment by Type
Capsule
Tablet
Segment by Application
Gallstone
Hepatopathy
Biliary Disease
Other
Consumption by Region
North America
the United States
Canada
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Drugs of UDCA manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Drugs of UDCA in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
The drug decreases the absorption of cholesterol and is used to dissolve (cholesterol) gallstones in patients as an alternative to a surgical procedure to remove the gallstones.
The global Drugs of UDCA market was valued at US$ 1645 million in 2023 and is anticipated to reach US$ 3389.8 million by 2030, witnessing a CAGR of 10.7% during the forecast period 2024-2030.
UDCA is a bile acid used in the treatment of various liver disorders, such as primary biliary cholangitis and primary sclerosing cholangitis. The increasing prevalence of these liver diseases, along with growing awareness about their diagnosis and treatment, is driving market growth. Additionally, advancements in drug formulations, such as the development of extended-release and combination therapies, are further contributing to market expansion. The market is highly competitive, with several pharmaceutical companies actively engaged in the production and distribution of UDCA drugs. However, challenges such as high drug costs, side effects, and limited accessibility in certain regions may hinder market growth.
This report aims to provide a comprehensive presentation of the global market for Drugs of UDCA, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drugs of UDCA.
Report Scope
The Drugs of UDCA market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Drugs of UDCA market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Drugs of UDCA manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Dr. Falk Pharma
Daewoong Pharmaceutical
Teva
Epic Pharma
Mitsubishi Tanabe Pharma
Lannett
Mylan
Bruschettini
Impax
Shanghai Pharma
Grindeks
Segment by Type
Capsule
Tablet
Segment by Application
Gallstone
Hepatopathy
Biliary Disease
Other
Consumption by Region
North America
the United States
Canada
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Drugs of UDCA manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Drugs of UDCA in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Drugs of UDCA Market Overview
1.1 Product Overview and Scope of Drugs of UDCA
1.2 Drugs of UDCA Segment by Type
1.2.1 Global Drugs of UDCA Market Value Comparison by Type (2024-2030)
1.2.2 Capsule
1.2.3 Tablet
1.3 Drugs of UDCA Segment by Application
1.3.1 Global Drugs of UDCA Market Value by Application: (2024-2030)
1.3.2 Gallstone
1.3.3 Hepatopathy
1.3.4 Biliary Disease
1.3.5 Other
1.4 Global Drugs of UDCA Market Size Estimates and Forecasts
1.4.1 Global Drugs of UDCA Revenue 2019-2030
1.4.2 Global Drugs of UDCA Sales 2019-2030
1.4.3 Global Drugs of UDCA Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Drugs of UDCA Market Competition by Manufacturers
2.1 Global Drugs of UDCA Sales Market Share by Manufacturers (2019-2024)
2.2 Global Drugs of UDCA Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Drugs of UDCA Average Price by Manufacturers (2019-2024)
2.4 Global Drugs of UDCA Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Drugs of UDCA, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Drugs of UDCA, Product Type & Application
2.7 Drugs of UDCA Market Competitive Situation and Trends
2.7.1 Drugs of UDCA Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Drugs of UDCA Players Market Share by Revenue
2.7.3 Global Drugs of UDCA Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Drugs of UDCA Retrospective Market Scenario by Region
3.1 Global Drugs of UDCA Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Drugs of UDCA Global Drugs of UDCA Sales by Region: 2019-2030
3.2.1 Global Drugs of UDCA Sales by Region: 2019-2024
3.2.2 Global Drugs of UDCA Sales by Region: 2025-2030
3.3 Global Drugs of UDCA Global Drugs of UDCA Revenue by Region: 2019-2030
3.3.1 Global Drugs of UDCA Revenue by Region: 2019-2024
3.3.2 Global Drugs of UDCA Revenue by Region: 2025-2030
3.4 North America Drugs of UDCA Market Facts & Figures by Country
3.4.1 North America Drugs of UDCA Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Drugs of UDCA Sales by Country (2019-2030)
3.4.3 North America Drugs of UDCA Revenue by Country (2019-2030)
3.4.4 the United States
3.4.5 Canada
3.5 Europe Drugs of UDCA Market Facts & Figures by Country
3.5.1 Europe Drugs of UDCA Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Drugs of UDCA Sales by Country (2019-2030)
3.5.3 Europe Drugs of UDCA Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 UK
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Drugs of UDCA Market Facts & Figures by Country
3.6.1 Asia Pacific Drugs of UDCA Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Drugs of UDCA Sales by Country (2019-2030)
3.6.3 Asia Pacific Drugs of UDCA Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Drugs of UDCA Market Facts & Figures by Country
3.7.1 Latin America Drugs of UDCA Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Drugs of UDCA Sales by Country (2019-2030)
3.7.3 Latin America Drugs of UDCA Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Drugs of UDCA Market Facts & Figures by Country
3.8.1 Middle East and Africa Drugs of UDCA Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Drugs of UDCA Sales by Country (2019-2030)
3.8.3 Middle East and Africa Drugs of UDCA Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Drugs of UDCA Sales by Type (2019-2030)
4.1.1 Global Drugs of UDCA Sales by Type (2019-2024)
4.1.2 Global Drugs of UDCA Sales by Type (2025-2030)
4.1.3 Global Drugs of UDCA Sales Market Share by Type (2019-2030)
4.2 Global Drugs of UDCA Revenue by Type (2019-2030)
4.2.1 Global Drugs of UDCA Revenue by Type (2019-2024)
4.2.2 Global Drugs of UDCA Revenue by Type (2025-2030)
4.2.3 Global Drugs of UDCA Revenue Market Share by Type (2019-2030)
4.3 Global Drugs of UDCA Price by Type (2019-2030)
5 Segment by Application
5.1 Global Drugs of UDCA Sales by Application (2019-2030)
5.1.1 Global Drugs of UDCA Sales by Application (2019-2024)
5.1.2 Global Drugs of UDCA Sales by Application (2025-2030)
5.1.3 Global Drugs of UDCA Sales Market Share by Application (2019-2030)
5.2 Global Drugs of UDCA Revenue by Application (2019-2030)
5.2.1 Global Drugs of UDCA Revenue by Application (2019-2024)
5.2.2 Global Drugs of UDCA Revenue by Application (2025-2030)
5.2.3 Global Drugs of UDCA Revenue Market Share by Application (2019-2030)
5.3 Global Drugs of UDCA Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Dr. Falk Pharma
6.1.1 Dr. Falk Pharma Corporation Information
6.1.2 Dr. Falk Pharma Description and Business Overview
6.1.3 Dr. Falk Pharma Drugs of UDCA Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Dr. Falk Pharma Drugs of UDCA Product Portfolio
6.1.5 Dr. Falk Pharma Recent Developments/Updates
6.2 Daewoong Pharmaceutical
6.2.1 Daewoong Pharmaceutical Corporation Information
6.2.2 Daewoong Pharmaceutical Description and Business Overview
6.2.3 Daewoong Pharmaceutical Drugs of UDCA Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Daewoong Pharmaceutical Drugs of UDCA Product Portfolio
6.2.5 Daewoong Pharmaceutical Recent Developments/Updates
6.3 Teva
6.3.1 Teva Corporation Information
6.3.2 Teva Description and Business Overview
6.3.3 Teva Drugs of UDCA Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Teva Drugs of UDCA Product Portfolio
6.3.5 Teva Recent Developments/Updates
6.4 Epic Pharma
6.4.1 Epic Pharma Corporation Information
6.4.2 Epic Pharma Description and Business Overview
6.4.3 Epic Pharma Drugs of UDCA Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Epic Pharma Drugs of UDCA Product Portfolio
6.4.5 Epic Pharma Recent Developments/Updates
6.5 Mitsubishi Tanabe Pharma
6.5.1 Mitsubishi Tanabe Pharma Corporation Information
6.5.2 Mitsubishi Tanabe Pharma Description and Business Overview
6.5.3 Mitsubishi Tanabe Pharma Drugs of UDCA Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Mitsubishi Tanabe Pharma Drugs of UDCA Product Portfolio
6.5.5 Mitsubishi Tanabe Pharma Recent Developments/Updates
6.6 Lannett
6.6.1 Lannett Corporation Information
6.6.2 Lannett Description and Business Overview
6.6.3 Lannett Drugs of UDCA Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Lannett Drugs of UDCA Product Portfolio
6.6.5 Lannett Recent Developments/Updates
6.7 Mylan
6.6.1 Mylan Corporation Information
6.6.2 Mylan Description and Business Overview
6.6.3 Mylan Drugs of UDCA Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Mylan Drugs of UDCA Product Portfolio
6.7.5 Mylan Recent Developments/Updates
6.8 Bruschettini
6.8.1 Bruschettini Corporation Information
6.8.2 Bruschettini Description and Business Overview
6.8.3 Bruschettini Drugs of UDCA Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Bruschettini Drugs of UDCA Product Portfolio
6.8.5 Bruschettini Recent Developments/Updates
6.9 Impax
6.9.1 Impax Corporation Information
6.9.2 Impax Description and Business Overview
6.9.3 Impax Drugs of UDCA Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Impax Drugs of UDCA Product Portfolio
6.9.5 Impax Recent Developments/Updates
6.10 Shanghai Pharma
6.10.1 Shanghai Pharma Corporation Information
6.10.2 Shanghai Pharma Description and Business Overview
6.10.3 Shanghai Pharma Drugs of UDCA Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Shanghai Pharma Drugs of UDCA Product Portfolio
6.10.5 Shanghai Pharma Recent Developments/Updates
6.11 Grindeks
6.11.1 Grindeks Corporation Information
6.11.2 Grindeks Drugs of UDCA Description and Business Overview
6.11.3 Grindeks Drugs of UDCA Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Grindeks Drugs of UDCA Product Portfolio
6.11.5 Grindeks Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Drugs of UDCA Industry Chain Analysis
7.2 Drugs of UDCA Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Drugs of UDCA Production Mode & Process
7.4 Drugs of UDCA Sales and Marketing
7.4.1 Drugs of UDCA Sales Channels
7.4.2 Drugs of UDCA Distributors
7.5 Drugs of UDCA Customers
8 Drugs of UDCA Market Dynamics
8.1 Drugs of UDCA Industry Trends
8.2 Drugs of UDCA Market Drivers
8.3 Drugs of UDCA Market Challenges
8.4 Drugs of UDCA Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
